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Abstract: Polycystic ovary syndrome (PCOS) is the most common female endocrine disorder and is
characterized by chronic anovulation, hyperandrogenism, and polycystic ovaries. Obesity, low-grade
chronic inflammatory status, and insulin-resistance (IR) often coexist in PCOS. The Mediterranean
diet (MD) is an anti-inflammatory dietary pattern, which is rich in complex carbohydrates and
fiber, and high in monounsaturated fat. There is a close association among obesity, low-grade
chronic inflammation, IR, and hormonal derangements in PCOS. The main aim of the present
study was to evaluate the adherence to MD, the dietary intake, and the body composition and their
association with PCOS clinical severity in a cohort of treatment-naïve women with PCOS when
compared with a control group of healthy women matched for age and body mass index (BMI). In
this case-controlled, cross-sectional study, we enrolled 112 patients with PCOS and 112 controls.
PREvención con DIetaMEDiterránea (PREDIMED) and seven-day food records were used to evaluate
the degree of adherence to the MD and dietary pattern, respectively. Body composition was
evaluated by bioelectrical impedance analysis (BIA) phase-sensitive system. Testosterone levels and
Ferriman-Gallwey score assessed the clinical severity of PCOS. C-reactive protein (CRP) levels were
determined with a nephelometric assay with CardioPhase high sensitivity. PCOS women showed
higher testosterone levels, Ferriman-Gallwey score, fasting insulin and glucose levels, and Homeostatic
Model Assessment (HoMA)-IR when compared with the control group (p < 0.001). In addition, we
found that the PCOS women consumed less extra-virgin olive oil, legumes, fish/seafood, and nuts
compared with control group. Despite no differences in energy intake between the two groups, the
PCOS women consumed a lower quantity of complex carbohydrate, fiber, monounsaturated fatty
acids (MUFA), and n-3 polyunsaturated fatty acid (PUFA), and higher quantity of simple carbohydrate,
total fat, saturated fatty acid (SFA), PUFA and n-6 PUFA than the control group. The PCOS women
have an adverse body composition when compared with controls, with the lowest values of phase
angle (PhA) and fat-free mass (p < 0.001). Additionally, after adjusting for BMI and total energy
intake, testosterone levels showed significant negative correlations with PREDIMED score (p < 0.001)
and consumption of protein (p = 0.005), complex carbohydrate (p < 0.001), fiber (p < 0.001), MUFA
(p < 0.001), n-3 PUFA (p = 0.001), and positive associations with CRP levels, simple carbohydrate,
SFA, n-6 PUFA (p < 0.001, respectively), and PUFA (p = 0.002). The cut-off for PREDIMED score ≤ 6
(p < 0.001, area under the curve (AUC) 0.848, standard error 0.036, 95% confidence interval (CI)
0.768 to 0.909) could serve as a threshold for significantly increased risk of high value of testosterone
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levels. In conclusion, a novel direct association between the adherence to MD and the clinical severity
of the disease was reported in women with PCOS. This association could support a therapeutic
role of foods and nutrients of the Mediterranean dietary pattern in the PCOS pathogenesis likely
involving their inflammatory status, IR, and hyperandrogenemia. In addition, we reported a different
body composition that is characterized by lower PhA and fat-free mass than controls. These data
suggested a role of PhA as a useful marker of the clinical severity of this syndrome and provided
strong evidence regarding the strategic relevance of the nutritional assessment in the management of
women with PCOS.
Keywords: Mediterranean Diet; Dietary pattern; Body Composition; Phase Angle; Polycystic Ovary
Syndrome (PCOS), Nutritionist
1. Introduction
Polycystic ovary syndrome (PCOS) is a multifactorial endocrine metabolic disorder [1] that
affects up to 18% of women of reproductive age [2]. PCOS is characterised by a spectrum of
different phenotypes and it is diagnosed when at least two of the three Rotterdam criteria are present:
(i) clinical hyperandrogenism (with hirsutism, acne, seborrhea, and alopecia) and/or with high
circulating androgens levels; (ii) presence of ovarian cysts assessed by ultrasound examination; and,
(iii) oligo-amenorrhea with oligo-anovulation [3]. In clinical practice, the Ferriman-Gallwey score
is an efficient tool for assessing hirsutism, which in turn is commonly correlated with biochemical
hyperandrogenism [4]. Beyond hormonal derangements, obesity, insulin-resistance (IR), with associated
compensatory hyperinsulinemia [5], and a low-grade chronic inflammatory status often coexist with
PCOS [6]. Although several studies have been carried out to investigate the association of metabolic
alterations and PCOS, it is still unknown why obesity is often a common finding in women with PCOS.
In particular, obesity and obesity-related low-grade inflammation both contribute to the onset of IR, by
amplifying the metabolic and reproductive outcomes [7]. IR and the compensatory hyperinsulinemia
might empower the androgenic activity, while the high levels of androgens may further blunt IR
through alterations of the body composition [8], which results in a vicious circle that leads to a
general worsening of this pathological status. Metabolic and endocrine derangements of PCOS both
contribute to making women with PCOS more prone to develop metabolic syndrome, type 2 diabetes
mellitus, and infertility [9–11]. Since obesity worsens the clinical presentation of PCOS, according
to the Recommendations from the International Evidence-based Guideline for the Assessment and
Management of PCOS, weight management is one of the main treatment strategies [12]. However, it is
still debated what is the best effective nutritional pattern that should be followed to lose weight in
PCOS. Among the different nutritional strategies, the Mediterranean diet (MD) is commonly recognised
as a health-promoting dietary pattern due to its peculiar features, including the regular consumption of
unsaturated fats, low glycaemic index carbohydrates, fiber, vitamins and antioxidants, and moderate
amount of animal-derived proteins [13]. In addition to weight loss, the MD has been reported to
have a well-established anti-inflammatory activity, which is mainly due to the microbiota-derived
production of short chain fatty acids that are induced by dietary fibre [14] and the high intake of
both polyunsaturated fatty acids (PUFA) omega 3 and antioxidants contained in fruits, vegetables,
extra-virgin olive oil, and wine [15–17]. However, no evidence is available in the literature regarding
to the association between the adherence to MD and the PCOS severity.
Beyond the MD, to date, few data are available on the dietary intake in women with PCOS by
using the seven-day food records, which is recognised as the “gold standard” for careful nutritional
assessments [18,19]. Douglas and colleagues (2006) estimated the dietary intake in women with PCOS
by using both a multiple-choice food questionnaire and a four-day food record and observed that,
although the intake of total energy and macro- and micronutrients were similar, PCOS women had a
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significantly higher intake of high glycaemic index foods (mainly white bread and fried potatoes) than
age- and body mass index (BMI)-matched controls [20].
In clinical practice, body composition is commonly measured by bioelectrical impedance analysis
(BIA), which is a non-invasive method for evaluation of body composition with a high agreement with
Dual-energy X-ray absorptiometry [21]. Phase angle (PhA) is a BIA-derived measure that is associated
with the inflammatory status. Studies investigating body composition by BIA reported that in PCOS
women higher metabolic dysfunction was associated with higher fat mass (FM) and fat-to-lean mass
ratio as compared to controls [22]. In addition, body fat percentage was positively associated with
levels of inflammatory biomarkers [23].
In this context, the main aim of the present study was to evaluate the adherence to MD, the dietary
intake assessed by seven-day food records, and the body composition assessed by BIA and their
association with PCOS clinical severity in a cohort of treatment-naïve women with PCOS as compared
with a control group of healthy women matched for age and BMI. When considering the coexistence
of both inflammation and obesity, and while taking into account the well-known anti-inflammatory
effects of MD, we suppose that PCOS women should be more prone to follow an unhealthy diet, poorly
adherent to the Mediterranean style, which contributes to worsening their condition; furthermore,
since various studies demonstrated the association between PhA and inflammation, we hypothesize to
find this relationship also in PCOS patients.
2. Materials and Methods
2.1. Design and Setting
This cross-sectional, observational study was carried out in patients with PCOS attending the Unit
of Endocrinology, Department of Clinical Medicine and Surgery, University Federico II of Naples (Italy),
from January 2014 to January 2019. The study has been approved by the Local Ethical Committee
(n. 05/14) and carried out in accordance with the Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments that involved humans. The aim of the study was clearly
explained to all of the study participants and a written informed consent was obtained.
2.2. Population Study
The subjects were enrolled at the outpatient Endocrinology clinic. The study included
112 treatment-naïve women that were affected by PCOS attending the Outpatient Clinic of the
Unit of Endocrinology in our Department.
One hundred-twelve Caucasian healthy subjects (ascertained by participant questionnaire
excluding the presence of clinical conditions that potentially influences fluid balance, i.e., myocardial,
renal, or endocrine diseases), age, and BMI matched were chosen as the controls among hospital
volunteers and employees from the same geographical area around Naples (Italy). To increase the
homogeneity of the patient sample, we only included treatment-naïve women.
Eligible patients were those with a diagnosis of PCOS classified by the European Society for
Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM)
diagnosis [3]. This includes the presence of two of the three features of hyperandrogenism (either
clinical (hirsutism by elevated Ferriman-Gallwey score) or biochemical (elevated testosterone or free
androgen index), oligomenorrhea (interval between two menstrual periods more than 35 days), or
amenorrhea (no vaginal bleeding for at least six months) and the presence of polycystic ovaries on
ultrasound scan (≥12 follicles measuring 2–9 mm in diameter, or ovarian volume >10 mL in at least
one ovary).
The inclusion criteria for all groups were: premenopausal women who were normal-weight,
overweight or obese (until BMI 39.9 kg/m2), aged 18–40 years, a lack of underlying metabolic
disease (type 2 diabetes, hypertension, diagnosed anemia, or any other metabolic disease requiring a
special diet).
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The exclusion criteria for all groups were the following:
1. Age < 18 years and > 40 years;
2. Menopause (defined as amenorrhea for ≥3 years or amenorrhea for ≥1 but <3 years and plasma
follicle-stimulating hormone concentrations elevated to the postmenopausal range); pregnancy
or lactation in the past 6 months;
3. Hyperandrogenism and/or biochemical hyperandrogenemia, oligomenorrhea due to secondary
etiologies as per the Endocrine Society Clinical Practice Guidelines and previous publications
including endocrine disorders (congenital adrenal hyperplasia, androgen-secreting tumors,
Cushing’s syndrome, hyperprolactinaemia, thyroid dysfunction and adrenal disorders) [24];
4. Pre-existing systemic or psychiatric disease and use of medications that impact carbohydrate or
lipid metabolism (oral contraceptive pills, metformin, anti-epileptics, anti-psychotics, statins and
fish oil);
5. Specific nutritional regimens or hypocaloric diet in the last three months, including vegan or
vegetarian diets; supplementation with antioxidants, vitamins or minerals;
6. Occasional or current of use of drugs that could influence fluid balance, including non-steroidal
anti-inflammatory drugs, diuretics, laxative use; and,
7. Women patients with implanted pacemakers or defibrillators because of the theoretical
possibility of interference with the device activity due to the field of current induced by the
impedance measurements.
The clinical and biochemical assessment were done between 8 am and 12 am, after an overnight fast.
2.3. Sample Size Justification and Power
The sample size was calculated on the basis of a previous study that reported prevalence of PCOS
as 12% in women of reproductive age [25]. The calculation of the sample size was performed by
considering two independent study groups; the effect size 0.95 with type I error of 0.05 and a power of
95%. The number of subjects to be enrolled was found to be 99 per group that we decided to round up
to 112 with a total of 224 total subjects being enrolled in the study to replace drop out patients.
The power was calculated by the differences of means ± standard deviation (SD) of PREvención
con DIetaMEDiterránea (PREDIMED) score in the PCOS patients and control group (6.97 ± 2.72 vs.
8.12 ± 2.80, respectively). When considering the number of cases required in each group of 100, were
set at 112 of group, a type I (alpha) error of 0.05 (85%), and a type II (beta) of 0.05, the calculated power
size was 85%. The calculation of sample size and power were performed while using Sample Size
Calculator Clinical Calc (https://clincalc.com/stats/samplesize.aspx).
2.4. Lifestyle Habits and Anthropometric Measurements
We defined smoking at least one cigarette per day as current smokers subjects, former smokers
were subjects who stopped smoking at least one year before the interview, and non-current smokers
the remaining participants. The participants habitually engaged in at least 30 min/day of aerobic
exercise (YES/NO) were defined as physically active, as we have already fully reported in previous
studies [26–28].
Measurements were performed between 8 am and 12 pm. All of the subjects were measured
after an overnight fast. The anthropometric measurements were performed by the same operator
(a nutritionist experienced in providing nutritional assessment and body composition), according to
the International Society for the Advancement of Kinanthropometry (ISAK 2006).
All of the anthropometric measurements were taken with subjects only wearing light clothes and
without shoes, as previously reported [27,29–31]. In each subject, weight and height were measured to
calculate the BMI (weight (kg) divided by height squared (m2), kg/m2). Height was measured to the
nearest 0.5 cm while using a wall-mounted stadiometer (Seca 711; Seca, Hamburg, Germany). Body
weight was determined to the nearest 0.1 kg while using a calibrated balance beam scale (Seca 711;
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Seca, Hamburg, Germany). BMI was classified according to World Health Organization’s criteria with
normal weight: 18.5–24.9 kg/m2; overweight, 25.0–29.9 kg/m2; grade I obesity, 30.0–34.9 kg/m2; grade II
obesity, 35.0–39.9 kg/m2 [32].
Waist circumference (WC) was measured to the closest 0.1 cm while using a non-stretchable
measuring tape at the natural indentation or at a midway level between lower edge of the rib cage
and iliac crest if no natural indentation was visible, in according to the National Center for Health
Statistics [33].
2.5. Nutritional Assessments
The adherence to the MD was assessed using PREDIMED questionnaire, consisting of 14 items [34].
A qualified nutritionist administered this questionnaire, which has already been used in previous
studies [35–38], during a face-to-face interview. Briefly, by assigning a score 1 and 0 for each items,
PREDIMED score was calculated, as follows: 0–5, lowest adherence; score 6–9, average adherence;
score ≥10, highest adherence [34].
As we have already fully reported in previous studies [39–42], the dietary assessments were
obtained by a face-to-face interview that a qualified nutritionist administered. In detail, a photographic
food atlas (≈1000 photographs) of known portion sizes was used to quantify foods and drinks [43] and
the seven-day food records were used to collect dietary data, including beverage intakes. On the basis
of these records, the nutritionist calculated the total energy intake and the quantities of macronutrients.
2.6. Body Composition
Body composition was assessed while using a BIA phase-sensitive system by experienced observers
(an 800-µA current at a frequency single-frequency of 50 kHz BIA 101 RJL, Akern Bioresearch, Florence,
Italy) [44], as previously reported [45–48]. The exam was performed as suggested by the European
Society of Parental and Enteral Nutrition (ESPEN) [49]. The electrodes were placed on the hand
and the ipsilateral foot, according to Kushner [50]. PhA is calculated as the relationship between
the resistance (R) of tissues, which is mainly dependent on tissue hydration and their reactance (Xc),
which is associated with cellularity, cell size, and integrity of the cell membrane [51–54], according
to the following formula: PhA (◦, degrees) = Xc/R * (180/pi). The same operator and the same device
obtained BIA determinations under strictly standardized conditions in order to avoid interobserver
and inter-device variability. The BIA was routinely checked with resistors and capacitors of known
values. Reliability for within-day and between-day measurements were <1.9% for R, <2.1% for Xc, and
<2.8% for R, <2.3% for Xc, respectively. The coefficient of variation (CV) of repeated measurements of
R and Xc at 50 kHz was assessed in 20 females (10 PCOS and 10 controls): CVs were 1.6% for R and
1.8% for Xc.
2.7. Assay Methods
The samples were collected in the morning between 8 and 10 am, after an overnight fast of at
least 8 h and stored at −80 ◦C until being processed. Fasting plasma glucose was analyzed with
a Roche Modular Analytics System in the Central Biochemistry Laboratory of our Institution. The
fasting insulin levels were measured by a solid-phase chemiluminescent enzyme immunoassay using
commercially available kits (Immulite Diagnostic Products Co., Los Angeles, CA, USA). Homeostasis
model assessment (HoMA)-IR was calculated according to Matthews et al. [55]. A value of HoMA-IR
>2.5 was used as cut-off of IR. C-Reactive Protein (CRP) levels were determined with a nephelometric
assay with CardioPhase high sensitivity from Siemens Healthcare Diagnostics (Marburg, Germany).
Serum testosterone was measured by chemiluminescent enzyme immunoassay (Immulite 2000,
Diagnostic Products Corp.). The intra- and inter-assay CV were <7% for all of the assays performed.
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2.8. Clinical Hyperandrogenism
The degree of hirsutism was evaluated, as originally described by Ferriman-Gallwey hirsutism
scoring scale, which measures nine androgen sensitive areas in the body [56]. A single Endocrinologist
performed the scoring assessment of each patient. Ferriman-Gallwey score evaluates 11 different body
parts, with scores ranging from 0 (no excessive terminal hair growth visible) to four (extensive hair
growth visible) for each body part evaluated. A maximum score of 36 is possible, but a score of >7 or
more was considered to be diagnostic of hirsutism, as defined by the 95th percentile of data initially
collected by Ferriman [57].
2.9. Statistical Analysis
The data distribution was evaluated by Kolmogorov-Smirnov test and data not normally
distributed were normalized by logarithm. Skewed variables (insulin, HoMA-IR, CRP levels,
testosterone, total carbohydrate intake, n-6 PUFA intake) were back-transformed for presentation
in tables and figures. The results are expressed as mean ± SD. The chi square (χ2) test was used
to determine the significance of differences in frequency distribution of smoking habit, physical
activity, BMI categories, WC cut-offs, adherence to the MD, and dietary components included in the
PREDIMED questionnaire.
Differences between PCOS patients and control group were analysed by Student’s independent
t-test, while the differences among the several parameters with the PREDIMED categories and CRP
levels, HoMA-IR, testosterone levels, and Ferriman-Gallwey score were analysed by between-groups
ANOVA test followed by the Bonferroni post-hoc test. The correlations between study variables were
performed while using Pearson r correlation coefficients after adjusting for BMI and total energy intake.
In addition, a multiple linear regression analysis model (stepwise method), expressed as R2, Beta (β)
and t, with testosterone levels as the dependent variable, was used to estimate the predictive value of
a food items, WC, PREDIMED score, CRP levels, HoMA-IR, and nutrient intake (protein, complex
carbohydrate, simple carbohydrate, saturated fat acid (SFA), monounsaturated fat acid (MUFA), PUFA,
n-6 PUFA, n-3 PUFA, fiber). Receiver operator characteristic (ROC) curve analysis were performed
to establish sensitivity and specificity, area under the curve (AUC), and confidence interval (IC), as
well as cut-off values for PREDIMED score in detecting testosterone levels that were above the median
values in the PCOS women. Test AUC for ROC analysis was also calculated and we entered 0.848 for
AUC ROC and 0.5 for null hypothesis values. An α level of 0.05 (type 1 error) and a β level of 0.20
(type II error) were used as the cut-off values for statistical significance. Only variables that had a
p-value < 0.05 in the univariate analysis (partial correlation) were entered. Variables with a variance
inflation factor (VIF) >10 were not considered to avoid multicollinearity. Values ≤ 5% were considered
to be statistically significant. Data were collected and analysed while using the MedCalc®package
(Version 12.3.0 1993–2012–Mariakerke, Belgium).
3. Results
The study population consisted of 224 participants, 112 patients with PCOS, and 112 women as
the control group. All of the cases and controls completed the study protocol, including the nutritional
assessment, the PREDIMED questionnaire, the seven-days food diary records, and BIA measurements.
Table 1 reports the lifestyle habits, anthropometric measurements, adherence to the MD, CRP
levels, hormonal, and biochemical parameters, the presence of clinical signs, and symptoms of
hyperandrogenism, and/or biochemical hyperandrogenemia of the cases and the controls matched for
age and BMI. As expected, the PCOS women showed higher testosterone levels, Ferriman-Gallwey
score, fasting insulin and glucose levels, and HoMA-IR when compared with the control group
(p < 0.001). Among the PCOS women, there were no differences in their smoking habits, physical
activity, and BMI categories, whereas more PCOS women presented WC >cut-off (p < 0.001) and a
lower adherence to the MD than controls (p < 0.001).
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Table 1. Lifestyle habits, anthropometric measurements, adherence to the Mediterranean diet (MD),
inflammatory parameter, hormonal, and biochemical parameters and clinical hyperandrogenism of the
case-patients and the subjects matched for age and BMI, serving as control group.
Parameters PCOS Patientsn = 112
Control Group
n = 112 p Values
Lifestyle Habits
Age (years) 24.21 ± 5.47 24.07 ± 5.05 0.721
Smoking χ2 = 0.10, p = 0.756
Yes (n, %) 29, 25.9% 26, 23.2%
No (n, %) 83, 74.1% 86, 76.8%
Physical activity χ2 = 0.08, p = 0.777
Sedentary (n, %) 76, 67.9% 73, 65.2%
Moderate (n, %) 36, 32.1% 39, 34.8%
Anthropometric measurements
BMI (kg/m2) 30.95 ± 5.66 30.76 ± 5.60 0.273
Normal-weight (n, %) 24, 21.4% 24, 21.4%
χ2 = 0.00, p = 1.000Over-weight (n, %) 29, 25.9% 29, 25.9%
Obesity I (n, %) 24, 21.4% 24, 21.4%
Obesity II (n, %) 35, 31.3% 35, 31.3%
WC (cm) 101.09 ± 16.29 92.54 ± 14.17 <0.001
WC< cut-off 20, 17.9% 43, 38.4%
χ2 = 10.69, p = 0.001WC > cut-off 92, 82.1% 69, 61.6%
Adherence to the MD
PREDIMED score 6.97 ± 2.72 8.12 ± 2.80 <0.001
Low adherence to the MD 37, 33.0% 21, 18.8% χ2 = 5.24, p = 0.022
Average adherence to the MD 53, 47.3% 58, 51.8% χ2 = 0.29, p = 0.593
High adherence to the MD 22, 19.6% 33, 29.5% χ2 = 2.41, p = 0.121
Inflammatory parameter
CRP levels (ng/mL) 1.03 ± 0.84 0.58 ± 0.44 <0.001
Hormonal and biochemical
parameters
Testosterone (ng/dL) 28.51 ± 9.82 10.21 ± 4.39 <0.001
Insulin (µU/mL) 11.61 ± 12.97 6.19 ± 7.79 <0.001
Fasting glucose (mg/dL) 94.92 ± 11.70 89.03 ± 10.89 <0.001
HoMA-IR 2.90 ± 3.59 1.45 ± 1.95 <0.001
Clinical Hyperandrogenism
Ferriman-Gallwey score 15.64 ± 9.69 2.47 ± 1.68 <0.001
The PCOS patients exhibited statistically significant differences compared to controls for WC, PREDIMED score,
CRP levels, hormonal, biochemical parameters and clinical hyperandrogenism. Results are expressed as mean ± SD.
The chi-square (χ2) test was used to determine the significance of differences in smoking habit, physical activity,
BMI categories, cut-off of WC and PREDIMED categories between the two groups. A p value in bold type denotes
a significant difference (p < 0.05). PCOS, Polycystic Ovarian Syndrome; BMI, Body Mass Index; WC, Waist
Circumference; MD, Mediterranean Diet, PREDIMED, PREvención con DIetaMEDiterránea; CRP, C-reactive Protein;
HoMA-IR, Homeostasis model assessment insulin resistance.
Analysing the response frequency of dietary components included in the PREDIMED questionnaire
in detail, we found that the PCOS women consumed less extra-virgin olive oil, legumes, fish/seafood,
and nuts, as compared with the control group (Table 2).
Data on Mediterranean food frequencies were further analysed by using the 7-day food records.
As shown in the Table 3, in spite of no differences in energy intake between the two groups, the PCOS
women consumed a lower quantity of complex carbohydrate, fiber, unsaturated fatty acids, MUFA,
and n-3 PUFA, and higher quantity of simple carbohydrate, total fat, SFA, PUFA, and n-6 PUFA than
the control group. The body composition that was assessed by BIA parameters of the PCOS women
and the control group are shown in Table 3. In particular, the PCOS women have lower values of
Xc (p = 0.028), PhA (p < 0.001), fat-free mass (FFM) (p < 0.001), total body water (TBW) (p = 0.001),
and intracellular water (ICW) (p = 0.004), and higher values of FM (p < 0.001) and extracellular water
(ECW) (p = 0.004) than the controls.
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Table 2. Response frequency of dietary components included in the PREvención con DIetaMEDiterránea
(PREDIMED) questionnaire of the polycystic ovary syndrome (PCOS) patients and control group.
Questions PREDIMED Questionnaire
PCOS Patients
n = 112
Control Group
n = 112 χ2 p Values
n % n %
Use of extra-virgin olive oil as main culinary lipid 88 78.6 108 96.4 14.74 <0.001
Extra virgin olive oil >4 tablespoons 64 57.1 55 49.1 1.15 0.284
Vegetables ≥2 servings/day 54 48.2 62 55.4 0.87 0.349
Fruits ≥3 servings/day 67 59.8 66 58.9 0.01 1.000
Red/processed meats <1/day 62 55.4 57 50.9 0.28 0.592
Butter, cream, margarine <1/day 47 42.0 55 49.1 0.88 0.348
Soda drinks <1/day 53 47.3 58 51.8 0.28 0.593
Wine glasses ≥ 7/week 30 26.8 35 31.3 0.35 0.555
Legumes ≥ 3/week 60 53.6 81 72.3 7.66 0.006
Fish/seafood ≥ 3/week 35 31.3 76 67.9 28.57 <0.001
Commercial sweets and confectionery ≤ 2/week 59 52.7 56 50.0 0.07 0.789
Tree nuts ≥ 3/week 31 27.7 76 67.6 34.64 <0.001
Poultry more than red meats 63 56.3 51 45.5 2.16 0.142
Use of sofrito sauce ≥ 2/week 68 60.7 73 65.2 0.31 0.580
PCOS patients exhibited statistically significant differences in use of extra-virgin olive oil as main culinary lipid,
legumes, fish/seafood, and nuts consumption, compared with control group. Results are expressed as number and
percentage of responses obtained with PREDIMED questionnaire. The differences were analysed by χ2 test. A
p value in bold type denotes a significant difference (p < 0.05). PREDIMED, PREvención con DIetaMEDiterránea;
PCOS, Polycystic Ovarian Syndrome.
Table 3. Daily energy, nutrients intake and bioelectrical impedance analysis (BIA) parameters of the
PCOS patients and control group.
Parameters PCOS Patientsn = 112
Control Group
n = 112 p-Value
Dietary Intake
Total energy (kcal) 2245.31 ± 290.75 2254.84 ± 272.37 0.711
Protein (g of total kcal) 86.98 ± 10.15 88.43 ± 9.96 0.261
Carbohydrate (g of total kcal) 307.98 ± 42.03 310.47 ± 37.42 0.518
Complex (g of total kcal) 174.21 ± 25.43 191.48 ± 23.60 <0.001
Simple (g of total kcal) 133.77 ± 34.01 118.99 ± 33.62 <0.001
Fiber (g/day) 15.43 ± 3.66 17.22 ± 4.19 <0.001
Fat (g of total kcal) 73.94 ± 13.59 70.07 ± 10.73 <0.001
SFA (g of total kcal) 24.55 ± 7.51 17.39 ± 10.71 <0.001
Unsaturated fat (g of total kcal) 49.38 ± 8.63 52.67 ± 8.12 0.002
MUFA (g of total kcal) 38.21 ± 4.56 43.68 ± 5.86 <0.001
PUFA (g of total kcal) 11.16 ± 6.88 8.99 ± 4.69 0.005
n-6 PUFA (g/day) 7.82 ± 6.83 4.67 ± 3.87 <0.001
n-3 PUFA (g/day) 3.34 ± 2.24 4.32 ± 3.29 <0.001
Body Composition
R (Ω) 488.71 ± 82.59 477.73 ± 71.79 0.289
Xc (Ω) 49.05 ± 10.09 51.58 ± 9.58 0.028
PhA (◦) 5.76 ± 0.71 6.20 ± 0.79 <0.001
FM (%) 34.47 ± 9.63 29.75 ± 9.88 <0.001
FFM (%) 65.44 ± 9.67 69.89 ± 10.07 <0.001
BCM (%) 49.92 ± 8.67 52.03 ± 9.92 0.082
TBW (%) 47.97 ± 7.06 49.99 ± 7.44 0.001
ECW (%) 47.20 ± 3.50 45.85 ± 3.92 0.004
ICW (%) 52.81 ± 3.51 54.15 ± 3.92 0.004
PCOS patients exhibited statistically significant differences compared with control group for dietary intake and BIA
parameters. In spite of no differences in energy intake between the two groups, PCOS patients have the lowest
intake of complex carbohydrate, fiber, unsaturated fatty acids, MUFA and n-3 PUFA, and higher quantity of simple
carbohydrate, total fat, SFA, PUFA and n-6 PUFA than control group. In addition, considering BIA parameters,
PCOS patients had a lowest values of Xc, PhA, FFM, TBW and ICW, and the highest values of FM and ECW. Results
are expressed as mean ± SD. Differences between groups were analysed by paired Student’s t test. A p value in bold
type denotes a significant difference (p < 0.05). BIA, Bioelectrical Impedance Analysis, PCOS, Polycystic Ovarian
Syndrome; SFA, Saturated Fatty Acids; MUFA, MonoUnsaturated Fatty Acids; PUFA, PolyUnsaturated Fatty Acids;
R, Resistance; Xc, Reactance; PhA, Phase angle; FM, Fat Mass, FFM, Fat-Free Mass, BCM, Body Mass Cell, TBW,
Total Body Water, ECW, Extra-cellular Water, ICW, Intra-cellular Water.
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The PCOS women were examined by stratifying above and below the median of testosterone
(22.27 ng/dL), (Table 4). The PCOS women that were above the median of testosterone had the
worse anthropometric measurements, adherence to the MD, CRP levels, hormonal and biochemical
parameters, dietary pattern, and body composition.
Table 4. Age, anthropometric measurements, adherence to the MD, inflammatory parameter, dietary
intake and body composition of the case-patients above and below the median of testosterone.
Parameters Testosterone (ng/dL)
< 22.27 ng/dL > 22.27 ng/dL p-Value
n = 56 n = 56
Age (years) 24.02 ± 5.74 24.41 ± 5.21 0.706
BMI (kg/m2) 27.39 ± 4.88 34.53 ± 3.85 <0.001
Normal-weight (n, %) 24, 42.9% 0, 0% <0.001
Over-weight (n, %) 20, 35.7% 9, 16.1% 0.031
Obesity I (n, %) 3, 5.4% 21, 37.5% <0.001
Obesity II (n, %) 9, 16.1% 26, 46.4% 0.001
WC (cm) 92.76 ± 12.69 109.42 ± 15.29 <0.001
WC > cut-off 37, 66.1% 55, 98.2% <0.001
Adherence to the MD
PREDIMED score 8.61 ± 2.37 5.34 ± 1.96 <0.001
Low adherence to the MD 7, 12.5% 0, 0% <0.001
Average adherence to the MD 27, 48.2% 30, 53.6% 0.999
High adherence to the MD 22, 39.3% 26, 46.4% <0.001
Inflammatory parameter
CRP levels (ng/dL) 0.51 ± 0.31 1.56 ± 0.88 <0.001
Hormonal and biochemical parameters
Insulin (µU/mL) 6.06 ± 7.85 17.16 ± 14.67 <0.001
Fasting glucose (mg/dL) 90.36 ± 10.97 99.48 ± 10.64 <0.001
HoMA-IR 1.39 ± 2.11 4.41 ± 4.13 <0.001
Dietary Intake
Total energy (kcal) 2141.83 ± 230.24 2348.78 ± 309.52 <0.001
Protein (g of total kcal) 88.01 ± 10.69 85.96 ± 9.55 0.287
Carbohydrate (g of total kcal) 292.29 ± 31.87 323.67 ± 45.26 <0.001
Complex (g of total kcal) 173.01 ± 20.24 175.41 ± 29.88 0.619
Simple (g of total kcal) 119.28 ± 26.68 148.25 ± 34.58 <0.001
Fiber (g/day) 17.08 ± 3.48 13.79 ± 3.04 <0.001
Fat (g of total kcal) 68.96 ± 10.70 78.92 ± 14.42 <0.001
SFA (g of total kcal) 20.51 ± 6.14 28.60 ± 6.54 <0.001
Unsaturated fat (g of total kcal) 48.45 ± 6.73 50.32 ± 10.16 0.254
MUFA (g of total kcal) 39.49 ± 3.45 36.94 ± 5.18 0.003
PUFA (g of total kcal) 8.96 ± 5.10 13.38 ± 7.71 0.001
n-6 PUFA (g/day) 5.51 ± 4.92 10.14 ± 7.69 <0.001
n-3 PUFA (g/day) 3.44 ± 2.28 3.23 ± 2.21 0.631
Body Composition
R (Ω) 504.93 ± 73.69 472.50 ± 88.31 0.037
Xc (Ω) 52.27 ± 8.96 45.83 ± 10.20 0.001
PhA (◦) 5.94 ± 0.65 5.57 ± 0.72 0.006
FM (%) 30.07 ± 9.19 38.86 ± 7.99 <0.001
FFM (%) 69.74 ± 9.33 61.14 ± 7.99 <0.001
BCM (%) 51.53 ± 7.95 48.31 ± 9.12 0.049
TBW (%) 51.19 ± 6.72 44.76 ± 5.85 <0.001
ECW (%) 46.29 ± 2.99 48.13 ± 3.76 0.005
ICW (%) 53.74 ± 3.02 51.88 ± 3.74 <0.001
The PCOS patients were examined by stratifying above and below the median of testosterone. PCOS patients
below the median of testosterone had the worse anthropometric measurements, adherence to the MD and CRP
levels, dietary pattern and body composition compared to the control group. Results are expressed as mean ± SD.
Differences between groups were analysed by paired Student’s t test. A p value in bold type denotes a significant
difference (p < 0.05). MD, Mediterranean Diet; BMI, Body Mass Index; WC, Waist Circumference; PREDIMED,
PREvención con DIetaMEDiterránea; CRP, C-reactive Protein; HoMA-IR, Homeostasis model assessment insulin
resistance; SFA, Saturated Fatty Acids; MUFA, MonoUnsaturated Fatty Acids; PUFA, PolyUnsaturated Fatty Acids;
R, Resistance; Xc, Reactance; PhA, Phase angle; FM, Fat Mass, FFM, Fat-free Mass, BCM, Body Mass Cell, TBW,
Total Body Water, ECW, Extra-cellular Water, ICW, Intra-cellular Water.
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In Figure 1 are reported the differences of CRP levels, HoMA-IR, testosterone levels, and
Ferriman-Gallwey score of the PCOS women on the basis of the PREDIMED categories. As shown in
Figure 1, the PCOS women with a low adherence to the MD presented higher CRP levels (Figure 1a),
HoMA-IR (Figure 1b), testosterone levels (Figure 1c), and Ferriman-Gallwey score (Figure 1d) than the
average and high adherers to the MD (p < 0.001, respectively).
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Figure 1. In Figure 1 were reported the differences of CRP levels, HoMA-IR, testosterone levels, and
Ferriman-Gallwey score of the PCOS women on the basis of the PREDIMED categories. As showed in
Figure 1, the PCOS women with a low adherence to the MD presented higher CRP levels (a), HoMA-IR
(b), testosterone levels (c), and Ferriman-Gallwey score (d) than average and high adherers to the MD
(p < 0.001, respectively). CRP, C-reactive protein; MD, Mediterranean diet; HoMA-IR, Homeostasis
model assessment insulin resistance; PCOS, Polycystic ovary syndrome; PREDIMED, PREvención con
DIetaMEDiterránea.
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Correlation Studies
The correlations between testosterone levels with anthropometric parameters, adherence to the
MD, CRP levels, dietary intake, and body composition of the PCOS women are summarized in Table 5.
Additionally, after adjusting for BMI, and total energy intake, testosterone levels showed significant
negative correlations with PREDIMED score (p < 0.001) and consumption of protein (p = 0.005),
complex carbohydrate (p < 0.001), fiber (p < 0.001), MUFA (p < 0.001), n-3 PUFA (p = 0.001), and positive
associations with WC, CRP levels, simple carbohydrate, SFA, n-6 PUFA (p < 0.001, respectively), and
PUFA (p = 0.002).
Table 5. Age, anthropometric measurements, adherence to the MD, inflammatory parameter, dietary
intake and body composition of the case-patients and the control group.
Testosterone Levels (ng/dL)
Parameters Simple Correlation After Adjusted for BMI and Total Energy
r p-Value r p-Value
Age (years) −0.034 0.725 −0.057 0.555
BMI (kg/m2) 0.720 <0.001 - -
WC (cm) 0.722 <0.001 0.399 <0.001
PREDIMED score −0.716 <0.001 −0.357 <0.001
CRP levels (ng/dL) 0.774 <0.001 0.677 <0.001
Insulin (µU/mL) 0.721 <0.001 0.490 <0.001
Fasting glucose (mg/dL) 0.517 <0.001 0.176 0.066
HoMA-IR 0.792 <0.001 0.485 <0.001
Total energy (kcal) 0.492 <0.001
Protein (g of total kcal) −0.167 0.078 −0.264 0.005
Carbohydrate (g of total kcal) 0.490 <0.001 −0.003 0.979
Complex (g of total kcal) −0.0.18 0.849 −0.365 <0.001
Simple (g of total kcal) 0.620 <0.001 0.419 <0.001
Fiber (g/day) −0.575 <0.001 −0.381 <0.001
Fat (g of total kcal) 0.551 <0.001 0.158 0.100
SFA (g of total kcal) 0.691 <0.001 0.321 0.001
Unsaturated fat (g of total kcal) 0.267 0.004 −0.018 0.850
MUFA (g of total kcal) −0.244 0.010 −0.444 <0.001
PUFA (g of total kcal) 0.497 <0.001 0.288 0.002
n-6 PUFA (g/day) 0.522 <0.001 0.412 <0.001
n-3 PUFA (g/day) −0.068 0.476 −0.314 0.001
R (Ω) −0.253 0.007 −0.071 0.460
Xc (Ω) −0.482 <0.001 −0.152 0.114
PhA (◦) −0.452 <0.001 −0.192 0.095
FM (%) 0.483 <0.001 −0.121 0.207
FFM (%) −0.474 <0.001 0.117 0.223
BCM (%) −0.322 0.001 0.005 0.957
TBW (%) −0.483 <0.001 0.121 0.209
ECW (%) 0.474 0.001 0.179 0.061
ICW (%) −0.475 0.001 −0.181 0.058
Correlations between testosterone levels with anthropometric parameters, adherence to the MD, CRP levels, dietary
intake and body composition of the PCOS women. Also after adjusting for BMI, and total energy intake, testosterone
levels showed significant correlations with PREDIMED score and some dietary nutrients. A p value in bold
type denotes a significant difference (p < 0.05). BMI, Body Mass Index; WC, Waist Circumference; PREDIMED,
PREvención con DIetaMEDiterránea; CRP, C-reactive Protein; HoMA-IR, Homeostasis model assessment insulin
resistance; SFA, Saturated Fatty Acids; MUFA, MonoUnsaturated Fatty Acids; PUFA, PolyUnsaturated Fatty Acids;
R, Resistance; Xc, Reactance; PhA, Phase angle; FM, Fat Mass, FFM, Fat-free Mass, BCM, Body Mass Cell, TBW,
Total Body Water, ECW, Extra-cellular Water, ICW, Intra-cellular Water.
As expected, CRP levels were negatively correlated with PREDIMED score and PhA (r = −0.717,
p < 0.001 and r = −0.493, p < 0.001), however, while the correlation with PhA was lost after adjusting
for BMI and total energy intake (r = −0.151, p = 0.114), the correlation with PREDIMED score and CRP
levels remained significant, even after adjusting for these potential confounders (r = −0.325, p = 0.001).
To assess the relative prognostic value of the WC, the adherence to the MD, CRP levels, HoMA-IR,
and daily energy and nutrients intake (protein, complex carbohydrate, simple carbohydrate, SFA,
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MUFA, PUFA, n-6 PUFA, n-3 PUFA, and fiber) to predict the clinical severity of PCOS, we performed a
multiple linear regression analysis model, including these parameters. While using this model, the
CRP levels entered at the first step (p < 0.001), followed by PREDIMED score (p < 0.001) and MUFA
intake (p = 0.001). As reported in Table 6, the model explained a total of 73.8% of the total variability,
including all three independent variables into the multiple regression.
Table 6. Multiple regression analysis model (stepwise method) with the Testosterone as dependent
variable to estimate the predictive value of food items of WC, PREDIMED score, CRP levels, HoMA-IR
and nutrients intake (protein, complex carbohydrate, simple carbohydrate, SFA, MUFA, PUFA, n-6
PUFA, n-3 PUFA, fiber).
Parameters Multiple Regression Analysis
Model 1 R2 β t p Value
CRP levels 0.704 −0.841 16.28 <0.001
PREDIMED SCORE 0.724 −0.212 −2.96 <0.001
MUFA (g of total kcal) 0.738 −0.133 −2.61 0.001
Variable excluded: WC, HoMA-IR, protein, complex carbohydrate, simple carbohydrate, SFA,
PUFA, n-6 PUFA, n-3 PUFA, fiber.
Between adherence to the MD and dietary nutrients intake, testosterone levels were well predicted by PREDIMED
score and MUFA intake. A p value in bold type denotes a significant difference (p < 0.05). CRP, C-reactive Protein;
PREDIMED, PREvención con DIetaMEDiterránea; MUFA, MonoUnsaturated Fatty Acids; WC, Waist Circumference;
HoMA-IR, Homeostasis model assessment insulin resistance; SFA, Saturated Fatty Acids; PolyUnsaturated
Fatty Acids.
The ROC analysis was performed to determine the cut off values of the PREDIMED score that was
predictive of the highest values of testosterone levels (above the median value 22.27 ng/dL) (Figure 2).
A value of PREDIMED score of ≤ 6 (p < 0.001, AUC 0.848, standard error 0.036, 95% CI 0.768 to 0.909)
could serve as a threshold for a significantly increased risk of high value of testosterone levels.
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4. Discussion
In this cross-sectional, observational study, we investigated the adherence to the MD, the dietary
intake assessed by seven-day food records, and the body composition assessed by BIA and their
associations with testosterone levels as index of PCOS clinical severity in a cohort of treatment-naïve
women with PCOS when compared with a control group of healthy women matched for age and BMI.
In particular, our results showed that the PCOS women had lower adherence to the MD and consumed
less extra-virgin olive oil, legumes, fish, and nuts than the controls. To the best of our knowledge,
this is the first study that investigated the adherence to the MD in PCOS women and the intake of
single nutrients.
In particular, the analysis of the seven-day food records showed that the PCOS women had
a different dietary pattern, with a higher consumption of simple carbohydrates and SFA, and low
consumption of complex carbohydrates, fiber, and MUFA as compared to controls. Of interest, this
unhealthy dietary pattern was associated with more severe hyperandrogenemia, inflammatory status
and IR. In particular, the inflammatory status, the adherence to the MD, and MUFA intake were the
factors that exerted the most powerful influence on testosterone levels. In addition, a PREDIMED score
≥6 was found as the most sensitive and specific cut-point to predict value of testosterone levels above
the median values.
The MD is a well-established health-promoting dietary pattern. In particular, there is evidence
that the adherence to the MD is inversely associated with adiposity [58], IR [59], and risk of type 2
diabetes mellitus [60] and cardiovascular disease [61]. On this basis, it was conceivable that MD might
be considered to be one of the best nutritional strategies also for the management of PCOS women.
The PREDIMED score results from a brief and useful 14-item questionnaire, validated for the
assessment of MD adherence [34,62]. The PREDIMED questionnaire is a versatile and practical tool for
obtaining a general and complete feedback about the participant dietary pattern in a short time [62,63].
According to the 14 items of the PREDIMED questionnaire, we reported that the intake of fish, nuts,
vegetables, and legumes was lower in PCOS women when compared to the control group. A further
novel finding of our study is the inverse association between the degree of adherence to the MD,
assessed by PREDIMED score and the clinical severity of PCOS. Interestingly, this relationship was still
significant when the data were adjusted for BMI and total energy intake, thus suggesting that MD might
play an independent role in mitigating the PCOS phenotype, probably through its anti-inflammatory
potential. In addition, we observed that, among the MD foods, the PCOS women consumed less
extra-virgin olive oil and nuts than the controls. These results seem to be of particular interest when
considering the nutraceutical potential of several MD foods, including extra-virgin olive oil, which
is one of the main components of this dietary pattern. In extra-virgin olive oil, indeed, a large body
of phenolic compounds has been identified and, among these, oleocanthal has been recognized as a
potent anti-inflammatory agent [64], due to its analogy with the chemical structure of ibuprofen [16].
On this basis, it is tempting to speculate that the long-term consumption of extra-virgin olive oil might
contribute to slow the progression of the inflammatory status, thus improving both insulin sensitivity
and compensatory hyperinsulinemia also in PCOS [65].
However, as diet is complex miscellanea of different foods and nutrients, the nutritional approach
should be based on a meticulous dietary assessment, in terms of quantity and quality, like the one that
was provided by the seven-day food records, the gold standard in self-administered food frequency
questionnaires. The analysis of seven-day food records showed that PCOS women consumed a higher
amount of high glycemic index carbohydrates, lower fiber, MUFA, and n-3 PUFA as compared to the
control group. These results are in line with previous studies reporting that a high intake of simple
carbohydrates exerts a pro-inflammatory effect, as demonstrated by increased CRP levels [66], and
they are responsible for increased oxidative stress, caused by postprandial hyperglycemia [67]. This
pro-inflammatory status might result in exacerbating IR, hyperandrogenism and inflammation in
women with PCOS [65]. Interestingly, it has been reported that specific nutrients, such as glucose, are
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able to stimulate the production of androgen by ovarian and directly promote inflammation in PCOS
women [65,68].
In parallel to carbohydrates, dietary fat, and in particular MUFA and n-3 PUFA, are also implicated
in the PCOS pathogenesis. In our study, we found that the lowest intake of MUFA was among the three
main predictors of the highest testosterone levels. The association between low MUFA consumption
in PCOS women is in agreement with the clinical trial performed by Kalgaonkar et al. [69]. MUFA
are considered as a healthy dietary fat and, traditionally, the beneficial effects of extra-virgin olive
oil have been attributed to its high MUFA content (oleic acid) as it protects lipoproteins and cellular
membranes from oxidative damage [70]. Most of the studies investigating the effects of n-3 PUFA in
PCOS women are clinical trials in which n-3 PUFA are administered as supplementation. A recent
meta-analysis of nine studies involving 591 subjects demonstrated that n-3 PUFA supplementation
improves the IR, reduces total cholesterol and triglycerides serum levels, and increases adiponectin
levels, which suggests that n-3 PUFA supplementation should be recommended for the metabolic
management of PCOS women [71]. Among these effects, however, the anti-inflammatory activity of
n-3 PUFA is undoubtedly one of the most important concern for the management of PCOS women.
Jamilian et al. [72] demonstrated that 12-week treatment with 1 g n-3 PUFA daily up-regulated PPAR-γ
expression and down-regulated IL-8 and TNF-α expression in peripheral blood mononuclear cells.
It is clear that unhealthy diets, besides the effects on inflammation and IR, could negatively affect
the body composition, which, in turn, is also responsible for worsening of the PCOS clinical severity.
Besides BMI, limited data are available on the body composition of PCOS women. No difference in
terms of body composition assessed by BIA has been detected in a pilot study that was performed on
adolescents with and without diagnosis of PCOS [11]. On the contrary, Ezeh et al. found that, in adult
PCOS women, the alteration in the fat-to-lean mass ratio that was evaluated by BIA could represent a
possible mechanism determining the increased IR in females [22]. Data herein presented show that
PCOS women have lower PhA and FFM as compared to age- and BMI-matched controls. These data
appear of interest considering the well-established relationship between higher adiposity, impaired
insulin sensitivity, and inflammatory status, which are all factors that are tightly involved in the
pathogenesis of PCOS. BIA is a common and validated method for the evaluation of body composition
in the clinical practice, with a high agreement with Dual X-ray Absorptiometry, also among patients
with severe obesity [21]. Although changes in the hydration status might cause errors in BIA measures,
PhA appears to represent a more suitable measurement, as it derives from the relationship between
resistance and Xc, two direct BIA measures [52] and its validity is also proven in cases of changes
in hydration status, such as in obesity and inflammation [73–75]. The PhA is an indicator of the
general health of cells [76] and water distribution [77]. Interestingly, PhA is related to body mass [78]
and ECW/ICW ratio [79], but it also represents as a valid parameter of the inflammation status in
cutaneous inflammatory diseases [46]. In our study, PhA was negatively associated not only with the
inflammatory status, but also with the hyperandrogenemia. Although these correlations were not kept
after adjustment for BMI and total energy intake, our results suggested that PhA might be considered
to be a marker of the severity of the PCOS.
We are aware that there are some limitations in the current study. First, the cross-sectional nature
of this study did not allow for any statements on a causal relationship between MD and clinical severity
of PCOS, especially when considering the adherence and dietary patterns through a previous lifespan.
Second, the sample size is relatively small and dietary intake is related to a larger number of other
lifestyle factors. Nevertheless, the sample size was calculated using 95% power; in addition, the
association between MD and testosterone levels was independent of the effects of other health-related
behaviours (BMI and total energy intake). Third, the PREDIMED score, although being easy to perform
by the participants, only allows relative but no absolute statements regarding the degree of adherence
to the MD. The PREDIMED questionnaire was face-to-face administered and not self-reported in order
to minimize any bias related to the filling of the questionnaire. In addition, to avoid the inter-operator
variability, only one expert Nutritionist evaluated the anthropometric measures, administered the
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PREDIMED questionnaire and seven-day food records, and assesses, executes, and interprets BIA
measurements. Anyway, the suggested cut-point for the PREDIMED score for identifying the highest
of testosterone levels should be viewed with caution until results of studies in larger population
samples have become available to perform an appropriate cross-validation.
Nevertheless, the main strength of this study is the use of the seven-day food records. This tool,
which is considered the “gold standard” in validation studies of different types of self-administered food
frequency questionnaires, allows for more accurate measurement of the real dietary and macronutrient
intakes as compared to those that were obtained by retrospective food frequency questionnaires [80].
Moreover, we increased the homogeneity of the patient sample by including only treatment-naïve
PCOS women, and matched controls in order to improve the power of the study.
5. Conclusions
In summary, in the present study, we reported for the first time in women with PCOS: (i) a
direct association between the adherence to MD and PCOS; (ii) a different body composition that is
characterized by low PhA and fat-free mass. These data could support a therapeutic role of single
foods and nutrients of the Mediterranean dietary pattern in the PCOS, by contributing to reduce the
inflammatory status that paves the way for IR and hyperandrogenemia. In addition, the role for PhA
as a useful marker of the clinical severity of PCOS is strongly suggested. Our data propose that the
strategic relevance of the nutritional assessment and body composition evaluation of women with
PCOS should be considered as the first and most important step in the management of this syndrome.
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